USP Awards Analytical Research - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Awards Analytical Research


The United States Pharmacopeial Convention (USP) has announced that an international group of three scientists are the recipients of USP’s 2014–2015 Global Fellowship Awards, aimed at advancing research involving quality standards for medicines. The recipients’ research will involve analytical tools useful in researching the safety of biopharmaceutical drugs, the detection of substandard drugs in the developing world, and the quality of dry powder inhaler products.

“The impact of encouraging scientists at the launch of their careers is something that extends far beyond the projects they undertake now, expanding the knowledge and skills they will carry to all future work,” noted USP chief executive officer Ronald T. Piervincenzi, PhD, in a press release. “As a student I was able to benefit from various research and fellowship programs, and I am very pleased that USP has a long-standing tradition of assisting future generations of researchers.”
Since the inception of the Global Fellowship Program in 1981, more than 200 scholars have received awards totaling nearly $4 million. The research supports USP’s mission to improve global health through public standards and programs that help ensure the quality, integrity, safety, and benefit of medicines and will also help address specific scientific needs.

Each of the following students has received a $30,000 USP Global Fellowship Award for the 2014–2015 academic year:

Khaja Muneeruddin, PhD candidate, University of Massachusetts-Amherst

Area of research: New mass spectrometry-based methods to characterize highly heterogeneous biopharmaceuticals
This project includes the development of novel analytical tools to characterize the natural diversity of biopharmaceutics, contributing to the safety of biopharmaceutical drugs. The methods developed under the guidance of Dr. Igor Kaltrashov, director of the chemistry department, will allow for thorough characterization of biopharmaceutical drugs to detect heterogeneity, which, in certain cases, affects their therapeutic activity.

Nicholas M. Myers, PhD candidate, University of Notre Dame

Area of research: Paper-based iodometric titration for quantification of antibiotics
This research is related to the Paper Analytical Device (PAD) project, which was primarily developed to test for counterfeit medications in developing countries, but the technology has also been adapted for other uses, such as testing for iodine deficiency. Led by Dr. Marya Lieberman, associate professor of chemistry and biochemistry, the PAD project uses paper-based technologies to test for the presence of specific chemicals in various substances. This technology is especially useful in low-resource settings where sophisticated lab equipment may not be available.

Ahmed O. Shalash, PhD candidate, Alexandria University, Egypt

Area of research: Investigation of performance descriptor(s) in carrier-based dry powder inhalers
The research deals with investigation of the role of carrier surface roughness. Under the supervision of professor of pharmacy Mohammed Khalafallah, the ultimate goal of the project is development of characterization techniques that express performance and are suitable for routine quality control of dry powder inhaler products. The possibility of replacing lactose with other carriers will also be studied.

Source: USP.org

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here